Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Innoviva Inc (INVA)

Innoviva Inc (INVA)
7.40 x 2 29.41 x 1
Post-market by (Cboe BZX)
18.50 +0.22 (+1.20%) 04/22/25 [NASDAQ]
7.40 x 2 29.41 x 1
Post-market 18.50 unch (unch) 16:20 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
18.30
Day High
18.52
Open 18.35
Previous Close 18.28 18.28
Volume 825,700 825,700
Avg Vol 913,090 913,090
Stochastic %K 95.91% 95.91%
Weighted Alpha +16.09 +16.09
5-Day Change +0.52 (+2.89%) +0.52 (+2.89%)
52-Week Range 14.89 - 21.28 14.89 - 21.28
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,145,717
  • Shares Outstanding, K 62,676
  • Annual Sales, $ 358,710 K
  • Annual Income, $ 23,390 K
  • EBIT $ 193 M
  • EBITDA $ 235 M
  • 60-Month Beta 0.48
  • Price/Sales 3.19
  • Price/Cash Flow 5.33
  • Price/Book 1.66

Options Overview Details

View History
  • Implied Volatility 48.90% ( -22.57%)
  • Historical Volatility 18.51%
  • IV Percentile 59%
  • IV Rank 34.55%
  • IV High 115.62% on 07/03/24
  • IV Low 13.67% on 06/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 116
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 247
  • Open Int (30-Day) 237

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.46
  • Growth Rate Est. (year over year) +217,073.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.67 +10.98%
on 04/10/25
Period Open: 17.27
18.52 -0.11%
on 04/22/25
+1.23 (+7.12%)
since 03/21/25
3-Month
16.67 +10.98%
on 04/10/25
Period Open: 18.53
19.39 -4.57%
on 01/27/25
-0.03 (-0.16%)
since 01/22/25
52-Week
14.89 +24.24%
on 04/23/24
Period Open: 14.93
21.28 -13.06%
on 11/12/24
+3.57 (+23.91%)
since 04/22/24

Most Recent Stories

More News
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva: Q3 Earnings Snapshot

Innoviva: Q3 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva: Q2 Earnings Snapshot

Innoviva: Q2 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva: Q1 Earnings Snapshot

Innoviva: Q1 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 18.50 (+1.20%)
Chart of the Day: Innoviva - Individual Investor Favorite

The Chart of the Day belongs to the biopharma company Innoviva (INVA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest...

INVA : 18.50 (+1.20%)
Innoviva: Q3 Earnings Snapshot

Innoviva: Q3 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva: Q2 Earnings Snapshot

Innoviva: Q2 Earnings Snapshot

INVA : 18.50 (+1.20%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

INVA : 18.50 (+1.20%)
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific...

INVA : 18.50 (+1.20%)
Innoviva: Q1 Earnings Snapshot

Innoviva: Q1 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva Announces Retirement of Board Chairman

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff...

INVA : 18.50 (+1.20%)
Markets Today: Stock Index Futures Climb as China’s Economy Strengthens

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.49% at a 2-month high, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.79% at a 2-week high. U.S. stock index futures this morning...

NVDA : 98.89 (+2.04%)
CVS : 65.45 (+0.43%)
MPC : 131.39 (+3.69%)
BAC : 38.32 (+3.79%)
JBHT : 128.52 (+1.10%)
JNJ : 157.75 (+0.53%)
BK : 76.31 (+3.07%)
BLU : 14.74 (unch)
GS : 519.99 (+3.72%)
NQM25 : 18,850.50 (+2.53%)
INVA : 18.50 (+1.20%)
ESM25 : 5,430.00 (+2.17%)
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial...

INVA : 18.50 (+1.20%)
Innoviva Stock Trading Halted Today

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Nasdaq has halted trading of Innoviva’s common...

INVA : 18.50 (+1.20%)
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA)...

INVA : 18.50 (+1.20%)
Innoviva: Q4 Earnings Snapshot

Innoviva: Q4 Earnings Snapshot

INVA : 18.50 (+1.20%)
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth...

INVA : 18.50 (+1.20%)
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

INVA : 18.50 (+1.20%)
ARMP : 1.3059 (+5.31%)
Four Undervalued Healthcare Stocks for 2023

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

INVA : 18.50 (+1.20%)
NOV : 12.16 (-0.98%)
EXEL : 36.48 (+2.50%)
REGN : 585.49 (+4.27%)
PFE : 22.53 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

3rd Resistance Point 18.80
2nd Resistance Point 18.66
1st Resistance Point 18.58
Last Price 18.50
1st Support Level 18.36
2nd Support Level 18.22
3rd Support Level 18.14

See More

52-Week High 21.28
Fibonacci 61.8% 18.84
Last Price 18.50
Fibonacci 50% 18.09
Fibonacci 38.2% 17.33
52-Week Low 14.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro